{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:59:35Z","timestamp":1793714375960,"version":"4.6.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Systemic and local recurrences of urothelial bladder cancer (UBC) significantly impair survival after radical cystectomy (RC), but little is known about the impact of the recurrence of urothelial cancer in the upper urinary tract (UTUC). This report describes survival outcomes and their predictors for patients who underwent RC followed by radical nephroureterectomy (RNU) for UTUC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The Surveillance, Epidemiology, and End Results database was queried to identify patients who underwent RC for UBC and subsequent RNU for UTUC. The Kaplan\u2013Meier method and competing-risk Cox regression (CRR) were used for the survival analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 102 patients have undergone RNU within a median of 49 months (interquartile range [IQR], 27\u201376 months) since RC. Muscle-invasive UTUCs were predominant at RNU (<jats:italic>n<\/jats:italic> = 58; 56.7%), but organ-confined bladder tumors were most frequent at RC (<jats:italic>n<\/jats:italic> = 42, 41.5%). After RNU, the estimated 5-year overall survival (OS) was 25.9%, the cancer-specific survival (CSS) was 35.6%, the median OS was 23 months (IQR, 11\u201363 months), and the CSS was 34 months (IQR, 13\u2013132 months). In the multivariable CRR, the factors predictive for CSS\u00a0after RNU\u00a0included male gender (hazard ratio [HR], 2.36; 95% confidence interval [CI], 1.03\u20135.42; <jats:italic>p<\/jats:italic> &lt; 0.05), muscle-invasive UTUC (HR, 2.20; 95% CI, 1.13\u20134.28; <jats:italic>p<\/jats:italic> &lt; 0.05), and the presence of distant metastasis (HR,11.59; 95% CI, 5.33\u201325.2; <jats:italic>p<\/jats:italic> &lt; 0.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In conclusion, the patients who underwent RNU for UTUC after RC for UBC experienced poor OS and CSS. The majority of RNUs were performed for locally advanced tumors. The independent risk factors for worse OS and CSS after RNU were UTUC T stage, presence of metastasis, and male gender.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-023-14710-x","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T16:12:10Z","timestamp":1702397530000},"page":"2144-2153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Upper Urinary Tract Urothelial Cancer After Radical Cystectomy for Bladder Cancer: Survival Outcomes After Radical Nephroureterectomy"],"prefix":"10.1245","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4344-0191","authenticated-orcid":false,"given":"Aleksander","family":"\u015alusarczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Zapa\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Piecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Zapa\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Borkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Radziszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"key":"14710_CR1","first-page":"590","volume":"38","author":"T van Doeveren","year":"2020","unstructured":"van Doeveren T, van de Werken HJG, van Riet J, Aben KKH, van Leeuwen PJ, Zwarthoff EC, et al. Synchronous and metachronous urothelial carcinoma of the upper urinary tract and the bladder: are they clonally related? A systematic review. Urol Oncol Semin Orig Investig. 2020;38:590\u20138.","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"14710_CR2","unstructured":"Professionals SO. Uroweb [cited 16 June 2021]. EAU guidelines: muscle-invasive and metastatic bladder cancer. Retrieved at https:\/\/uroweb.org\/guideline\/bladder-cancer-muscle-invasive-and-metastatic\/"},{"key":"14710_CR3","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s11255-019-02183-5","volume":"51","author":"A \u015alusarczyk","year":"2019","unstructured":"\u015alusarczyk A, Zapa\u0142a P, Zapa\u0142a \u0141, Piecha T, Radziszewski P. Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics. Int Urol Nephrol. 2019;51:1089\u201399.","journal-title":"Int Urol Nephrol"},{"key":"14710_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.eururo.2016.09.035","volume":"71","author":"G Gakis","year":"2017","unstructured":"Gakis G, Black PC, Bochner BH, Boorjian SA, Stenzl A, Thalmann GN, et al. Systematic review on the fate of the remnant urothelium after radical cystectomy. Eur Urol. 2017;71:545\u201357.","journal-title":"Eur Urol"},{"key":"14710_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1464-410X.2007.06841.x","volume":"100","author":"KM Sanderson","year":"2007","unstructured":"Sanderson KM, Roupr\u00eat M. Upper urinary tract tumour after radical cystectomy for transitional cell carcinoma of the bladder: an update on the risk factors, surveillance regimens and treatments. BJU Int. 2007;100:11\u20136.","journal-title":"BJU Int"},{"key":"14710_CR6","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1016\/j.juro.2012.08.017","volume":"188","author":"S Picozzi","year":"2012","unstructured":"Picozzi S, Ricci C, Gaeta M, Ratti D, Macchi A, Casellato S, et al. Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients. J Urol. 2012;188:2046\u201354.","journal-title":"J Urol"},{"key":"14710_CR7","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.juro.2017.03.120","volume":"198","author":"Q Li","year":"2017","unstructured":"Li Q, Assel M, Benfante N, Pietzak E, Bagrodia A, Cha E, et al. Clinical outcomes in patients with panurothelial carcinoma treated with radical nephroureterectomy following cystectomy for metachronous recurrence. J Urol. 2017;198:546\u201351.","journal-title":"J Urol"},{"key":"14710_CR8","doi-asserted-by":"publisher","first-page":"732.e1","DOI":"10.1016\/j.urolonc.2021.03.002","volume":"39","author":"J Aumatell","year":"2021","unstructured":"Aumatell J, Huguet J, Subiela JD, Gaya JM, Faba \u00d3R, Territo A, et al. Endoscopic exploration directly impacts clinical decision-making in the management of patients with suspected upper tract urothelial carcinoma following radical cystectomy. Urol Oncol. 2021;39:732.e1-e8.","journal-title":"Urol Oncol"},{"key":"14710_CR9","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1200\/JCO.1998.16.3.1099","volume":"16","author":"HW Herr","year":"1998","unstructured":"Herr HW. Extravesical tumor relapse in patients with superficial bladder tumors. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16:1099\u2013102.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"14710_CR10","first-page":"306.e9","volume":"36","author":"N Nishiyama","year":"2018","unstructured":"Nishiyama N, Hotta H, Takahashi A, Yanase M, Itoh N, Tachiki H, et al. Upper tract urothelial carcinoma following intravesical bacillus Calmette\u2013Gu\u00e9rin therapy for nonmuscle-invasive bladder cancer: results from a multi-institutional retrospective study. Urol Oncol Semin Orig Investig. 2018;36:306.e9-e15.","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"14710_CR11","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.eururo.2014.11.043","volume":"67","author":"BH Bochner","year":"2015","unstructured":"Bochner BH, Dalbagni G, Sjoberg DD, Silberstein J, Keren Paz GE, Donat SM, et al. Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized clinical trial. Eur Urol. 2015;67:1042\u201350.","journal-title":"Eur Urol"},{"key":"14710_CR12","doi-asserted-by":"publisher","first-page":"841852","DOI":"10.3389\/fonc.2022.841852","volume":"12","author":"\u0141 Zapa\u0142a","year":"2022","unstructured":"Zapa\u0142a \u0141, \u015alusarczyk A, Korczak B, Kurzyna P, Leki M, Lipi\u0144ski P, et al. The view outside of the box: reporting outcomes following radical cystectomy using Pentafecta from a multicenter retrospective analysis. Front Oncol. 2022;12:841852.","journal-title":"Front Oncol."},{"key":"14710_CR13","first-page":"28","volume":"75","author":"T Hladun","year":"2022","unstructured":"Hladun T, Ratajczak J, Salagierski M. Can we lower the rates of cystectomy complications by modifying risk factors? A review of the literature. Cent Eur J Urol. 2022;75:28\u201334.","journal-title":"Cent Eur J Urol"},{"key":"14710_CR14","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/JU.0000000000002211","volume":"207","author":"T Miest","year":"2022","unstructured":"Miest T, Khanna A, Sharma V, Hensley PJ, Campbell R, Thapa P, et al. Development and validation of a risk-adapted scoring model for metachronous upper tract urothelial carcinoma following radical cystectomy. J Urol. 2022;207:284\u201392.","journal-title":"J Urol"},{"key":"14710_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.urology.2020.07.034","volume":"153","author":"TS Miest","year":"2021","unstructured":"Miest TS, Sharma V, Boeri L, Tollefson MK, Thompson RH, Boorjian SA, et al. Does ureteral stent drainage prior to cystectomy increase the risk of subsequent upper tract urothelial carcinoma and ureteral complications? Urology. 2021;153:215\u201320.","journal-title":"Urology"},{"issue":"236","key":"14710_CR16","first-page":"e13","volume":"34","author":"SB Stewart-Merrill","year":"2016","unstructured":"Stewart-Merrill SB, Alahdab F, Benkhadra K, Wang Z, Sorita A, Boorjian SA, et al. Oncologic surveillance in bladder cancer following radical cystectomy: a systematic review and meta-analysis. Urol Oncol. 2016;34(236):e13-21.","journal-title":"Urol Oncol"},{"key":"14710_CR17","first-page":"257","volume":"75","author":"J Correia","year":"2022","unstructured":"Correia J, Mendes G, Texeira B, Madanelo M, Fraga A, Silva-Ramos M. Perioperative and oncological outcomes of laparoscopic and open radical nephroureterectomy for locally advanced upper tract urothelial carcinoma: a single-center cohort study. Cent Eur J Urol. 2022;75:257\u201364.","journal-title":"Cent Eur J Urol"},{"key":"14710_CR18","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1007\/s11255-023-03655-5","volume":"55","author":"A \u015alusarczyk","year":"2023","unstructured":"\u015alusarczyk A, Zapa\u0142a P, Olszewska-\u015alusarczyk Z, Radziszewski P. The prediction of cancer-specific mortality in T1 non-muscle-invasive bladder cancer: comparison of logistic regression and artificial neural network: a SEER population-based study. Int Urol Nephrol. 2023;55:2205\u201313. https:\/\/doi.org\/10.1007\/s11255-023-03655-5.","journal-title":"Int Urol Nephrol"},{"issue":"12","key":"14710_CR19","doi-asserted-by":"publisher","first-page":"7892","DOI":"10.1245\/s10434-023-14051-9","volume":"30","author":"A \u015alusarczyk","year":"2023","unstructured":"\u015alusarczyk A, Zapa\u0142a P, Zapa\u0142a \u0141, Borkowski T, Radziszewski P. Cancer-specific survival of patients with non-muscle-invasive bladder cancer: a population-based analysis. Ann Surg Oncol. 2023;30(12):7892\u2013902.","journal-title":"Ann Surg Oncol"},{"key":"14710_CR20","first-page":"490.e13","volume":"40","author":"M Ferro","year":"2022","unstructured":"Ferro M, Barone B, Crocetto F, Lucarelli G, Busetto GM, Del Giudice F, et al. Predictive random-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer. Urol Oncol Semin Orig Investig. 2022;40:490.e13-e20.","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"14710_CR21","doi-asserted-by":"publisher","DOI":"10.5114\/aoms\/130303","author":"A \u015alusarczyk","year":"2021","unstructured":"\u015alusarczyk A, Piotr Z, Garbas K, Zapa\u0142a \u0141, Borkowski T, Radziszewski P. Blood count-derived inflammatory markers predict time to Bacillus Calmette\u2013Gu\u00e9rin failure in high-risk non-muscle-invasive bladder cancer. Arch Med Sci. 2021. https:\/\/doi.org\/10.5114\/aoms\/130303.","journal-title":"Arch Med Sci"},{"key":"14710_CR22","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","volume":"395","author":"A Birtle","year":"2020","unstructured":"Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomized controlled trial. Lancet. 2020;395:1268\u201377.","journal-title":"Lancet"},{"key":"14710_CR23","doi-asserted-by":"publisher","first-page":"4660","DOI":"10.3390\/cancers15184660","volume":"15","author":"A \u015alusarczyk","year":"2023","unstructured":"\u015alusarczyk A, Zapa\u0142a P, Piecha T, Rajwa P, Moschini M, Radziszewski P. The association between lymph node dissection and survival in lymph node-negative upper urinary tract urothelial cancer. Cancers. 2023;15:4660.","journal-title":"Cancers"},{"key":"14710_CR24","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1016\/j.juro.2009.02.021","volume":"181","author":"M Roscigno","year":"2009","unstructured":"Roscigno M, Shariat SF, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, et al. Impact of lymph node dissection on cancer-specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol. 2009;181:2482\u20139.","journal-title":"J Urol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14710-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-14710-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14710-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T19:10:43Z","timestamp":1706987443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-14710-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["14710"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-14710-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,12]]},"assertion":[{"value":"10 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"Due to the character of the study, no Ethics Committee approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}